In the BioHarmony Drug Report Database
Emapalumab-lzsg
Gamifant (emapalumab) is an antibody pharmaceutical. Emapalumab was first approved as Gamifant on 2018-11-20. It is used to treat hemophagocytic lymphohistiocytosis in the USA. The pharmaceutical is active against interferon gamma.
Trade Name
|
Gamifant |
|---|---|
Common Name
|
emapalumab |
ChEMBL ID
|
CHEMBL3989977 |
Indication
|
hemophagocytic lymphohistiocytosis |
Drug Class
|
Monoclonal antibodies: fully human, immunomodulating |
Image (chem structure or protein)
